InflaRx (IFRX) Cash & Current Investments (2016 - 2026)
InflaRx (IFRX) posted Cash & Current Investments of $46.6 million for Q1 2026, down 13.84% sequentially from $54.1 million in Q4 2025, and down 6.79% YoY from $50.0 million in Q1 2025.
InflaRx (IFRX) Cash & Current Investments (2016 - 2026) Analysis & Trends
InflaRx has reported Cash & Current Investments for 11 years, with the latest figure at $46.6 million in Q1 2026.
- Quarterly Cash & Current Investments fell 6.79% year-over-year to $46.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.6 million (down 6.79% YoY) and the FY2025 annual result came in at $52.5 million, down 8.26% from the prior year.
- Cash & Current Investments retreated to $46.6 million in Q1 2026 per IFRX's latest filing, from $54.1 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $101.0 million in Q1 2022 and troughed at $10.8 million in Q1 2023.
- A 5-year average of $40.2 million and a median of $41.9 million in 2023 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2023 and 2024: Cash & Current Investments tumbled 89.31% in 2023, then soared 177.44% in 2024.
- Over 5 years, Cash & Current Investments stood at $19.6 million in 2022, then gained by 20.06% to $23.5 million in 2023, then surged by 140.6% to $56.5 million in 2024, then dropped by 4.27% to $54.1 million in 2025, then fell by 13.84% to $46.6 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $46.6 million, $54.1 million, and $52.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 184.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.60 Mn |
| Dec 31, 2025 | 54.08 Mn |
| Sep 30, 2025 | 52.19 Mn |
| Jun 30, 2025 | 54.33 Mn |
| Mar 31, 2025 | 49.99 Mn |
| Dec 31, 2024 | 56.49 Mn |
| Sep 30, 2024 | 63.58 Mn |
| Jun 30, 2024 | 20.88 Mn |
| Mar 31, 2024 | 29.98 Mn |
| Dec 31, 2023 | 23.48 Mn |
| Sep 30, 2023 | 23.88 Mn |
| Jun 30, 2023 | 41.89 Mn |
| Mar 31, 2023 | 10.80 Mn |
| Dec 31, 2022 | 19.55 Mn |
| Sep 30, 2022 | 18.37 Mn |
| Jun 30, 2022 | 16.70 Mn |
| Mar 31, 2022 | 101.03 Mn |
| Dec 31, 2021 | 61.15 Mn |
| Sep 30, 2021 | 34.74 Mn |
| Jun 30, 2021 | 153.18 Mn |